EGFR and cancer: As previously observed in a variety of cancer models1,3,13,17, a functional signature of this EGFR-TKI persisters (i.e., erlotinib) is the capacity to revert back to sensitivity after an extended drug holiday (previous experimental observations vary from 20 to 40 passages).